title: [Role of mutations on the "hepatitis B virus 'a' determinant hotpoint" to the efficacy of hepatitis B vaccine].
abstract: OBJECTIVE
  To study how hepatitis B virus(HBV) 'a' determinant hotpoint mutations were influecing the hepatitis B vaccine efficacy.
  
  
  METHODS
  Primers were designed in HBV conservative region, and the degenerate probes for detecting 16 'a' determinant hotpoint mutations were developed for gene chips. Sensitivity and specificity of the gene chips were evaluated by clone sequencing. Sera of 47 pairs of mothers and infants with immune failure and 323 mothers of children with immune protection of HB vaccine were detected by the gene chips.
  
  
  RESULTS
  Result from clone sequencing demonstrated that the gene chips were specific for the detection of 'a' determinant hotpoint mutations. The wild type of HBV was still dominant, with the prevalence of 78.66%, and the mutation frequencies of 126A, 145R, 126S-1, 126S-2, 129H, 144A, and 129R were 11.27%, 5.76%, 5.28%, 4.56%, 1.20%, 0.72% and 0.24%, respectively. The prevalence of 126A mutation was significantly higher than that of other mutations(P < 0.01). No significant differences were found in mother-infant transmission rates of 126A, 126S-1, 126S-2 and 145R variants.
  
  
  CONCLUSIONS
  The currently available hepatitis B vaccine could block mother-infant transmission of 126A, 126S and 145R variants. It appears that there is no need to develop a new hepatitis B vaccine against 126 and 145 variants at present, but the consistent epidemiological surveillance on HBV mutants should be carried out.
authors.affiliation: National Institute for the Control of Pharmaceutical and Biological Products, Beijing 100050, China.
authors.forename: Rui
authors.initials: R
authors.lastname: Zhang
authors.forename: Rong-cheng
authors.initials: RC
authors.lastname: Li
authors.forename: Feng-cai
authors.initials: FC
authors.lastname: Zhu
authors.forename: Yan-ping
authors.initials: YP
authors.lastname: Li
authors.forename: She-lan
authors.initials: SL
authors.lastname: Liu
authors.forename: Xian-chen
authors.initials: XC
authors.lastname: Zhang
authors.forename: Sheng-qi
authors.initials: SQ
authors.lastname: Wang
authors.forename: Zheng-lun
authors.initials: ZL
authors.lastname: Liang
authors.forename: He-min
authors.initials: HM
authors.lastname: Li
authors.forename: Hui
authors.initials: H
authors.lastname: Zhuang
mesh_terms: D000328:Adult; D005260:Female; D005838:Genotype; D006509:Hepatitis B / Q000517:prevention & control* / Q000635:transmission; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006515:Hepatitis B virus / Q000235:genetics* / Q000276:immunology; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D009154:Mutation; D020411:Oligonucleotide Array Sequence Analysis; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control / Q000821:virology*
chemical_list: D017325:Hepatitis B Vaccines